Cargando…
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory receptor expressed on several types of lymphocytes. Efficacy of antibody blockade of TIGIT in cancer immunotherapy is currently widely being investigated in both pre-clinical and clinical studies. In multiple cancers TIGIT is ex...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339559/ https://www.ncbi.nlm.nih.gov/pubmed/34367161 http://dx.doi.org/10.3389/fimmu.2021.699895 |